PD-ECGF-targeted tumor imaging with new radiolabeled uracil derivatives
Project/Area Number |
20790906
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Radiation science
|
Research Institution | Hokkaido University |
Principal Investigator |
NISHIJIMA Ken-ichi Hokkaido University, 大学院・医学研究科, 特任講師 (60364254)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 放射性医薬品 / 血管新生 / Thymidine Phosphorylase / 血小板由来血管内皮細胞増殖因子 / イメージング / Thmidine Phoshorlase |
Research Abstract |
The angiogenic factor PD-ECGF/TP is expressed at high levels in a variety of solid tumors compared with normal tissue. In this study, we aimed at the development of radiopharmaceuticals for imaging of angiogenesis. To develop a radioprobe for angiogenesis imaging, a radiolabeled uracil-based PD-ECGF/TP inhibitor, BOMU and IIMU were designed and radiosynthesized. These radiolabeled uracil derivatives showed high and specific accumulation of in PD-ECGF/TP-expressing tumors. These finding indicate that radiolabeled uracil deserves further evaluation as a novel single photon emission computed tomography (SPECT) probe for imaging of tumor angiogenesis.
|
Report
(4 results)
Research Products
(20 results)